ENDYMED Announces Full Merger with Its Majority Shareholder and Distributor in China, Strengthening Global Market Position

FREEHOLD, N.J., March 6, 2025 /PRNewswire/ -- ENDYMED Ltd ("ENDYMED"), is proud to announce the successful completion of its full merger with its majority shareholder Shanghai Haohai Biological Technology Co., Ltd. ("Haohai").

This strategic consolidation not only strengthens ENDYMED's presence in the Chinese market but also enhances its global reach, operational efficiency, market competitiveness and strengthen its market competitiveness—all while directly benefiting customers.

By merging with its controlling shareholder, ENDYMED gains increased strategic flexibility, expanded resources, and enhanced decision-making capabilities on a global scale. This unified structure enables the company to streamline its global supply chain, accelerate innovation, and strengthen its position in key international markets.

"This merger marks a transformative step for ENDYMED, enabling us to better serve our customers globally while maintaining strong local market expertise," said Yossi Bar-On, CEO of ENDYMED. "By fully integrating with our majority shareholder and trusted Chinese distributor, we're unlocking new efficiencies and capabilities that directly benefit our clients—delivering faster, smarter, and more effective solutions."

"This strategic move not only strengthens our global presence but also enhances the value we bring to our customers," added Dr. Hou, Chairman of HAOHAI and ENDYMED. "Together, we're positioned to drive innovation, operational excellence, and sustainable growth worldwide."

About Haohai
Haohai is a technology innovative enterprise that utilizes biomedical material technology and genetic engineering technology for the research, development, production, and sales of medical devices and pharmaceuticals. Haohai was listed on the main board of the Hong Kong Stock Exchange and the Shanghai Stock Exchange STAR Market on April 30, 2015, and October 30, 2019, respectively, making it the first "Hong Kong Stock + SSE STAR Market" biopharmaceutical listed company in China. It remains committed to the rapidly evolving fields of ophthalmology, medical aesthetics & wound care, orthopedics, and surgery.

About ENDYMED
ENDYNMED is a leading medical technology company specializing in energy-based aesthetic treatment systems. ENDYMED - FDA-cleared 3DEEP^® RF technology is one of the most clinically validated in the industry, powering professional and home-use devices used by physicians and clinics.
EndyMed was founded to develop innovative solutions for skin rejuvenation, body contouring, microneedling, fractional skin resurfacing, wrinkle and scar treatment, and skin tightening.
ENDYMED continues to shape the future of non-invasive aesthetic treatments, combining science, safety, and superior results to meet the evolving needs of professionals and patients worldwide.

SOURCE ENDYMED Ltd